Add-on anti-TGF-β antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat

Journal of the American Society of Nephrology

Volumn 14, Issue 7, 2003, Pages 1816-1824

  Benigni, Ariela ^a   Zoja, Carla ^a   Corna, Daniela ^a   Zatelli, Cristina ^a   Conti, Sara ^a   Campana, Marco ^a   Gagliardini, Elena ^a   Rottoli, Daniela ^a   Zanchi, Cristina ^a   Abbate, Mauro ^a   Ledbetter, Steve ^c   Remuzzi, Giuseppe ^a,b  

^a MARIO NEGRI INST PHARMACOL RES   (Italy)

^b OSPEDALI RIUNITI   (Italy)

^c GENZYME CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 3; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL; MONOCLONAL ANTIBODY; SODIUM CHLORIDE; STREPTOZOCIN; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG ACTIVITY; DRUG MECHANISM; GLOMERULOSCLEROSIS; KIDNEY INTERSTITIUM; KIDNEY TUBULE; LYMPHOCYTE; MACROPHAGE; MALE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEINURIA; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE;

EID: 0038205926     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ASN.0000074238.61967.B7     Document Type: Article

References (42)

1. Hostetter T: Prevention of end-stage renal disease due to type 2 diabetes. N Engl J Med 345: 910-911, 2001
2. King H, Aubert R, Herman W: Global burden of diabetes, 1995-2025: Prevalence, numerical estimates, and projection. Diabetes Care 21: 1414-1431, 1998
3. Parving H-H, Osterby R, Ritz E: Diabetic nephropathy. In: The Kidney, edited by Brenner BM, Philadelphia, WB Saunders, 2000, p. 1731
4. Remuzzi G, Schieppati A, Ruggenenti P: Nephropathy in patients with type 2 diabetes. N Engl J Med 346: 1145-1151, 2002
5. Remuzzi G, Bertani T: Pathophysiology of progressive nephropathies. N Engl J Med 339: 1448-1456, 1998
6. Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner BM: Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 77: 1925-1930, 1986
7. Perico N, Amuchastegui CS, Malanchini B, Bertani T, Remuzzi G: Angiotensin-converting enzyme inhibition and calcium channel blockade both normalize early hyperfiltration in experimental diabetes, but only the former prevents late renal structural damage. Exp Nephrol 2: 220-228, 1994
8. Perico N, Amuchastegui SC, Colosio V, Sonzogni G, Bertani T, Remuzzi G: Evidence that an angiotensin converting enzyme inhibitor has a different effect on glomerular injury according to the different phase of the disease at which the treatment is started. J Am Soc Nephrol 5: 1139-1146, 1994
9. Microalbuminuria Collaborative Study Group United Kingdom: Risk factors for development of microalbuminuria in insulin dependent diabetic patients: A cohort study. Br Med J 306: 1235-1239, 1993
10. Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M: Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 118: 577-581, 1993
11. Parving H-H, Lehnert H, Brochner Mortensen J, Gomis R, Andersen S, Arner P: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345: 870-878, 2001
12. Ruggenenti P, Remuzzi G: Nephropathy of type 1 and type 2 diabetes: diverse pathophysiology, same treatment? Nephrol Dial Transplant 15: 1900-1902, 2000
13. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving H-H, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869, 2001
14. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851-860, 2001
15. Sakharova OV. Taal MW, Brenner BM: Pathogenesis of diabetic nephropathy: focus on transforming growth factor-β and connective tissue growth factor. Hypertension 10: 727-738, 2001
16. Reeves WB, Andreoli TE: Transforming growth factor β contributes to progressive diabetic nephropathy. PNAS 97: 7667-7669, 2000
17. Wolf G, Ziyadeh FN: Molecular mechanisms of diabetic renal hypertrophy. Kidney Int 56: 393-405, 1999
18. Gilbert RE, Cooper ME: The tubulointerstium in progressive diabetic kidney disease: More than an aftermath of glomerular injury? Kidney Int 56: 1627-1637, 1999
19. Park IS, Kiyomoto H, Abboud SL, Abboud HE: Expression of transforming growth factor-beta and type IV collagen in early streptozotocin-induced diabetes. Diabetes 46: 473-480, 1997
20. Sharma K, Jin Y, Guo J, Ziyadeh FN: Neutralization of TGF-β by anti-TGF-β antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 45: 522-530, 1996
21. Gilbert RE, Cox A, Wu LL, Allen TJ, Hulthen UL, Jerums G, Cooper ME: Expression of transforming growth factor-β1 and type IV collagen in the renal tubulointerstitium in experimental diabetes. Diabetes 47: 414-422, 1998
22. Yamamoto T, Nakamura T, Noble NA, Ruoslahti E, Border WA: Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. PNAS 90: 1814-1818, 1993
23. Ziyadeh FN, Sharma K, Ericksen M, Wolf G: Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-β J Clin Invest 93: 536-542, 1994
24. Rocco MV, Chen Y, Goldfarb S, Ziyadeh FN: Elevated glucose stimulates TGF-β gene expression and bioactivity in proximal tubule. Kidney Int 41: 107-114, 1992
25. Wolf G, Mueller E, Stahl RAK, Ziyadeh FN: Angiotensin II-induced hypertrophy of cultured murine proximal tubular cells is mediated by endogenous transforming growth factor-β. J Clin Invest 92: 1366-1372, 1993
26. Yard BA, Chorianopoulos E, Herr D, van der Woude FJ: Regulation of endothelin-1 and transforming growth factor-betal production in cultured proximal tubular cells by albumin and heparan sulphate glycosaminoglycans. Nephrol Dial Transplant 16: 1769-1775, 2001
27. Ziyadeh FN, Hoffman BB, Cheol Han D, Iglesias-de la Cruz MC, Won Hong S, Isono M, Chen S, McGowan TA, Sharma K: Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-β antibody in db/db diabetic mice. PNAS 97: 8015-8020, 2000
28. Dasch JR, Pace DR, Waegell W, Inenaga D, Ellingsworth L: Monoclonal antibodies recognizing transforming growth factor-β. Bioactivity neutralization and transforming growth factor beta 2 affinity purification. J Immunol 142: 1536-1541, 1989
29. Read SM, Northcote DH: Minimization of variation in the response to different proteins of the Coomassie blue G dye-binding assay for protein. Anal Biochem 116: 53-64, 1981
30. Dahly AJ, Hoagland KM, Flasch AK, Jha S, Ledbetter SR, Roman RJ: Antihypertensive effects of chronic anti-TGF-β antibody therapy in Dahl S rats. Am J Physiol 283: R757-R767, 2002
31. Lapinski R, Benigni A, Perico N, Remuzzi G: Angiotensin II modulates glomerular capillary permselectivity in rat isolated perfused kidney. J Am Soc Nephrol 7:653-660, 1996
32. Sharma R, Khanna A, Sharma M, Savin VJ: Transforming growth factor-beta1 increases albumin permeability of isolated rat glomeruli via hydroxyl radicals. Kidney Int 58: 131-136, 2000
33. White KE, Bilous RW: Type 2 diabetic patients with nephropathy show structural-functional relationships that are similar to type 1 disease. J Am Soc Nephrol 11: 1667-1673, 2000
34. Border WA, Noble NA: Transforming growth factor β in tissue fibrosis. New Engl J Med 331: 1286-1292, 1994
35. Utimura R, Fujihara CK, Mattar AL, Avancini Costa Malheiros DM, de Lourdes Noronha I, Zatz R: Mycophenolate mofetil prevents the development of glomerular injury in experimental diabetes. Kidney Int 63: 209-216, 2003
36. Kato S, Luyckx VA, Ots M, Lee K-W, Ziai F, Troy JL, Brenner BM, Mackenzie HS: Renin-angiotensin blockade lowers MCP-1 expression in diabetic rats. Kidney Int 56: 1037-1048, 1999
37. Adams DH, Hathaway M, Shaw J, Burnett D, Elias E, Strain AJ: Transforming growth factor-β induces human T lymphocyte migration in vitro. J Immunol 147: 609-612, 1991
38. Wiseman DM, Polverini PJ, Kamp DW, Leibovich SJ: Transforming growth factor-beta (TGF-β) is chemotactic for human monocytes and induces their expression of angiogenic activity. Biochem Biophys Res Commun 157: 793-800, 1988
39. Kelly FJ, Anderson S, Thompson MM, Oyama TT, Kennefick TM, Corless CL, Roman RJ, Kurtzberg L, Pratt BM, Ledbetter SR: Acute and chronic renal effects of recombinant human TGF-beta2 in the rat. J Am Soc Nephrol 10: 1264-1273, 1999
40. Fong CY, Pang L, Holland E, Knox AJ: TGF-β1 stimulates IL-8 release, COX-2 expression, and PGE2 release in human airway smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 279: L201-L207, 2000
41. Matsumura Y, Murata S, Takada K, Takaoka M, Morimoto S: Involvement of transforming growth factor-beta 1 for platelet-induced stimulation of endothelin-1 production. Clin Exp Pharmacol Physiol 21: 991-996, 1994
42. Inoue N, Venema RC, Sayegh HS, Ohara Y, Murphy TJ, Harrison DG: Molecular regulation of the bovine endothelial cell nitric oxide synthase by transforming growth factor-β1. Arterioscler Thromb Vasc Biol 15: 1255-1261, 1995